Welcome to our dedicated page for TANDEM DIABETES CARE SEC filings (Ticker: TNDM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TANDEM DIABETES CARE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TANDEM DIABETES CARE's regulatory disclosures and financial reporting.
Tandem Diabetes Care, Inc. reported results of its 2026 annual stockholder meeting and related governance changes. Stockholders approved amendments to the Amended and Restated Certificate of Incorporation to allow removal of directors with or without cause and to limit officer liability to the maximum extent permitted by Delaware law.
They also approved an amendment to the 2023 Long-Term Incentive Plan increasing the shares of common stock authorized for issuance under the plan by 3,260,000 shares. All nine director nominees were elected, executive compensation was approved on a non-binding advisory basis, and Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026.
There were 68,504,233 shares of common stock outstanding on the March 23, 2026 record date, and 57,964,375 shares were present virtually or by proxy at the meeting, reflecting strong stockholder participation in the governance and compensation decisions.
Tandem Diabetes (TNDM) filing under Rule 144 reports an intended sale of 266 shares of Common stock tied to Restricted Stock Units, dated 05/15/2026. The filing also lists prior 10b5-1 sales by Mark Novara of 187 shares on 03/17/2026 and 2 shares on 03/05/2026.
Tandem Diabetes Care EVP & Chief Technology Officer Rick Carpenter reported routine equity compensation activity involving restricted stock units and an employee stock purchase plan. On May 15, 2026, he acquired 1,336 shares of common stock at $10.90 through the company’s employee stock purchase plan and vested RSUs that converted into shares.
To cover tax obligations on these RSU vestings, 4,466 shares were withheld by the company at $12.82 per share, and footnotes clarify that no shares were sold in the market. After all transactions, Carpenter directly held 25,979 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care executive Elizabeth Anne Gasser reported several compensation-related stock transactions dated May 15, 2026. She exercised restricted stock units into a total of 10,267 shares of common stock at a stated price of $0.00 per share and received a separate grant of 1,337 shares at $10.90 per share.
To cover tax obligations on these vestings, the company withheld 5,510 shares at $12.82 per share, and the footnotes state that no shares were sold. After these transactions, she directly holds 1,762 shares of common stock and indirectly holds 25,949 shares through The Gasser Family Trust. A footnote also notes voluntary reporting of an acquisition under the company’s Employee Stock Purchase Plan for a period ending May 15, 2026.
Tandem Diabetes Care EVP & Chief Legal Officer Shannon M. Hansen reported routine equity compensation activity in company stock. On May 15, 2026, she exercised restricted stock units covering a total of 10,201 shares of common stock, and 5,192 shares were withheld by the company to satisfy tax obligations; footnotes state no shares were sold on the market. She also voluntarily reported acquiring 1,886 shares through the company’s Employee Stock Purchase Plan at $10.90 per share. Following these transactions, she directly holds 28,285 shares of common stock and indirectly holds 1,935 shares through the Shannon M. Hansen Trust.
Tandem Diabetes Care EVP & COO Jean-Claude Kyrillos reported routine equity compensation activity involving restricted stock units (RSUs), tax withholding, and an employee stock purchase. On May 15, 2026, 4,038 RSUs converted into common stock and 2,139 shares were withheld to cover taxes, with no shares sold. He also acquired 434 shares through the company’s employee stock purchase plan. Following these transactions, he directly holds 27,671 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care EVP & Chief Administrative Officer Susan Morrison reported a series of routine equity compensation transactions in company stock. She acquired 9,523 shares of common stock through the vesting and conversion of restricted stock units and 1,336 shares through the employee stock purchase plan at $10.90 per share.
To cover tax obligations on these vestings, 2,724 shares were withheld by the company, and no shares were sold on the open market. After these transactions, Morrison directly holds 43,708 shares of common stock.
Tandem Diabetes Care President and CEO John F. Sheridan reported routine equity compensation activity in common stock. On May 15, 2026, he acquired 1,336 shares at $10.90 per share through the company’s Employee Stock Purchase Plan. Several restricted stock unit awards vested and were exercised into a total of 51,189 shares of common stock. To cover related tax obligations, 24,773 shares were withheld by the company at $12.82 per share, and the footnotes state that no shares were sold on the market.
Tandem Diabetes Care EVP & Chief Financial Officer Leigh Vosseller reported several equity compensation transactions in company stock. On May 15, 2026, she exercised restricted stock units converting a total of 13,495 shares of common stock, and 4,843 shares were withheld by the company to cover tax obligations, with no shares sold. She also acquired 1,336 shares through the company’s Employee Stock Purchase Plan at $10.90 per share. Following these transactions, she directly holds 40,374 shares of common stock and an additional 25,580 shares are held indirectly through the Leigh A. Vosseller Trust.
Tandem Diabetes Care EVP & Chief Commercial Officer Mark David Novara reported routine equity compensation activity. On May 15, 2026, he acquired a total of 10,572 shares of common stock through the vesting and conversion of restricted stock units. To cover tax obligations on these vestings, 7,911 shares were withheld by the company at a reference price of $12.82 per share, and the footnotes state that no shares were sold in the market.